TriangleNCT00753688 · OUTCOME
Time to Response Assessed by an Independent Radiologist and the Investigator
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- weeks
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From the date of randomization until the date of the first documented evidence of CR or PR (assessed for an average of 10 months)
What was measured
Time to response was defined as the time from the date of randomization until the date of first documented evidence of CR or PR (whichever status was recorded first). The Kaplan-Meier method was used for time to response estimates.
Analysis population: ITT Population. Only participants who achieved a confirmed CR or PR, as determined independently by the Independent Radiologist and the Investigator, were analyzed. Only results for the pazopanib arm are given because there was no response in the placebo arm.
Groups in this outcome
Placebo
Matching placebo tablets administered orally once daily for a duration until participants experienced disease progression, death, unacceptable toxicity, or participants withdrew consent
Pazopanib
Pazopanib 200 milligrams (mg) and 400 mg film-coated tablets (containing pazopanib monohydrochloride) administered orally at a dose of 800 mg once daily for a duration until participants experienced disease progression, death, unacceptable toxicity, or participants withdrew consent
| Group | Source count |
|---|---|
| Placebo | 0 |
| Pazopanib | 23 |
Reported measurements
Independent radiologist assessed, n=0, 11
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Pazopanib | 8.4 | Not reported | 4.7 | 19.1 | Not reported |
Investigator assessed, n=0, 23
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Pazopanib | 8.1 | Not reported | 4.6 | 11.7 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG001
- lower Limit
- 4.7
- upper Limit
- 19.1
- value
- 8.4
- title
- Independent radiologist assessed, n=0, 11
- categories
- measurements
- group Id
- OG001
- lower Limit
- 4.6
- upper Limit
- 11.7
- value
- 8.1
- title
- Investigator assessed, n=0, 23
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 23
- units
- Participants
- description
- Time to response was defined as the time from the date of randomization until the date of first documented evidence of CR or PR (whichever status was recorded first). The Kaplan-Meier method was used for time to response estimates.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Matching placebo tablets administered orally once daily for a duration until participants experienced disease progression, death, unacceptable toxicity, or participants withdrew consent
- id
- OG000
- title
- Placebo
- description
- Pazopanib 200 milligrams (mg) and 400 mg film-coated tablets (containing pazopanib monohydrochloride) administered orally at a dose of 800 mg once daily for a duration until participants experienced disease progression, death, unacceptable toxicity, or participants withdrew consent
- id
- OG001
- title
- Pazopanib
- param Type
- MEDIAN
- population Description
- ITT Population. Only participants who achieved a confirmed CR or PR, as determined independently by the Independent Radiologist and the Investigator, were analyzed. Only results for the pazopanib arm are given because there was no response in the placebo arm.
- reporting Status
- POSTED
- time Frame
- From the date of randomization until the date of the first documented evidence of CR or PR (assessed for an average of 10 months)
- title
- Time to Response Assessed by an Independent Radiologist and the Investigator
- type
- SECONDARY
- unit Of Measure
- weeks
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice